PET Scan to Track T-DXd in Breast Cancer
Part of Cancer, Skin clinical trials.
This trial tests a special PET scan that can see how well the drug T-DXd is working in your body. If you have advanced breast cancer and are already taking T-DXd, this study will help your doctor track your treatment more precisely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have locally advanced or metastatic breast cancer and your doctor recommends treatment with a drug called T-DXd (Trastuzumab deruxtecan).
- You are already taking part in the OASIS study (a larger research project).
- You have at least two tumors that are 1.5 cm or larger and show up on a PET scan.
- You are willing and able to follow the study's schedule and procedures.
- You have not been treated with T-DXd before.
- You are not allergic to the study's PET imaging agents, claustrophobic, or unable to stay still for 30 minutes.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a special type of PET scan can predict how well a targeted cancer drug (T-DXd) will work for patients with advanced breast cancer that has specific HER2 markers. The goal is to help doctors personalize treatment decisions based on imaging results.
This trial uses a blood test to look for tumor DNA in women with a certain type of advanced breast cancer (HR-positive, HER2-low). If the DNA doesn't disappear after starting standard hormone therapy with a CDK4/6 inhibitor, participants may be switched to a targeted drug called T-DXd (trastuzumab deruxtecan).
This study tests how well trastuzumab deruxtecan (T-DXd) works for people with HER2-low breast cancer that has spread. The treatment is given as part of routine care, and the trial uses advanced imaging (PET/CT) to measure response.
This trial tests how well an imaging test can predict the effectiveness of the drug T-DXd in people with HER2-positive breast cancer that has spread to the brain. It aims to see if a special scan can help guide treatment.
This trial is studying a drug called T-DXd (trastuzumab deruxtecan) for Chinese women with advanced breast cancer that has a certain protein (HER2) either in high or low amounts. It aims to see how well the drug works in real-world settings.
This trial is for people with advanced HER2-positive solid tumors (cancers that cannot be removed by surgery or have spread). It tests the drug T-DXd (also called Enhertu) when your doctor has already decided it's the right treatment for you and you have no other good options.
Hear when a new Locally Advanced or Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.